The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://luckxih248405.bloguerosa.com/37833939/glp-3-retatrutide-a-comparative-analysis